Ketosis: Clinical Trials

281 trials for Ketosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

152 completed, 48 unknown, 34 recruiting, 15 not yet recruiting. 164 Not applicable, 33 Phase 2, 20 Phase 1, 11 Phase 3, 11 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable164Completed 102, Unknown 27, Recruiting 15, Not yet recruiting 7, Terminated 7, Withdrawn 4, Active not recruiting 2
Phase 233Completed 8, Recruiting 8, Unknown 8, Not yet recruiting 3, Active not recruiting 2, Enrolling by invitation 2, Withdrawn 2
Phase 120Completed 10, Not yet recruiting 2, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1, Suspended 1, Withdrawn 1
Phase 311Completed 3, Recruiting 3, Active not recruiting 2, Enrolling by invitation 1, Unknown 1, Withdrawn 1
Phase 411Completed 6, Recruiting 2, Terminated 2, Not yet recruiting 1
Early Phase 13Recruiting 2, Completed 1

Follow Ketosis: new trials by email Literature Review of Ketosis trials Research Report on Ketosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Sotagliflozin initiation - Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
Phase 2Not yet recruitingHealthPartners Institute802027-01-012026-10-23
The BRIGHT Study (Device Name: HALO System)
The HALO System - Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Not applicableNot yet recruitingIndigo Diabetes NV122026-12-012026-08-04
Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder
Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis
Phase 2 / Phase 3RecruitingUniversity of Pennsylvania602026-12-012026-10-21
Acute Effects of Ketone Monoester Co-Ingestion With Dietary Protein on Whole-Body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Older Males
Ketone Monoester + Dietary Protein (KET+PRO), Dietary Protein (PRO), Resistance Exercise - Ketosis, Resistance Exercise
Not applicableNot yet recruitingMcGill University182026-11-012026-10-20
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
PAL-119, Placebo - Healthy Volunteers and Diabetes Participants
Phase 1 / Phase 2Not yet recruitingPaulex Bio Inc.1472026-11-012026-10-28
LIfestyle MEtabotype Study B (LIME-B)
βHB drink (ketone ester), Carbohydrate drink - Nutritional and Metabolic Diseases, Prediabetes
Not applicableRecruitingGerman Institute of Human Nutrition3002026-10-262026-10-28
Acute Effects of Ketone Monoester Co-ingestion With Dietary Protein on Whole-body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Young Males.
Ketone Monoester + Dietary Protein (KET+PRO), Dietary Protein (PRO), Resistance Exercise - Post-exercise Period, Ketosis
Not applicableRecruitingMcGill University182026-10-232026-10-23
Perfusion Index for Predicting Diabetic Ketoacidosis Severity in the Emergency Department
Diabetic Ketoacidosis
RecruitingAnkara Etlik City Hospital1402026-09-152026-09-16
Leukocyte Glucose Index and Severity of Diabetic Ketoacidosis
Diabetic Ketoacidosis, Diabetes Mellitus
Not yet recruitingAssiut University1202026-09-102026-09-16
Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fasting in Critical Illness
Delayed nutrition, Standard nutrition, Fasting - Critical Illness, Fasting State
Not applicableNot yet recruitingKarolinska University Hospital2002026-08-312026-09-01
Combining Fasting and Fibre Interventions to Optimise Their Gut Microbiome-mediated Health Benefits
Fibre Arm, Control Arm - Fasting, Dietary Fibre
Not applicableRecruitingBuchinger Wilhelmi Development & Holding GmbH752026-08-312026-09-30
Ketones for Opioid Craving
Treatment with Ketone Supplement, Treatment with Placebo - Opioid Use Disorder
Phase 2RecruitingUniversity of Maryland, Baltimore502026-07-162026-08-25
Exogenous Ketone Supplementation in ICU Delirium
Ketone monoester, Placebo - ICU Delirium, Critical Illness
Phase 2RecruitingVanderbilt University Medical Center402026-06-092026-08-24
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies
Metabolic Diseases, Diabetes Mellitus (Type 2)
Not yet recruitingCentre Hospitalier Universitaire de la Guadeloupe1182026-06-012026-05-08
Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure
Ketone Monoester (KE) - Acute Heart Failure (AHF), Cardiogenic Shock
Phase 4RecruitingInstitute for Clinical and Experimental Medicine122026-04-042026-04-14
Ketogenic Diet for Post-Traumatic Stress Disorder (PTSD)
Ketogenic diet - Post-Traumatic Stress Disorder, PTSD
Not applicableCompletedBundeswehr University Munich62026-03-122026-08-13
Hemodynamic Effects of Ketone Esters in Patients With Sepsis Induced Cardiomyopathy
Ketone ester, Placebo - Sepsis Induced Cardiomyopathy
Not applicableNot yet recruitingTor Biering-Sørensen122026-03-102026-03-04
Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes
CIR-0602K, Placebo - Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus
Phase 2RecruitingUniversity of Virginia402026-02-222026-02-25
Undiluted and Diluted Nutrition
Enteral fluid, Intravenous fluid - Critical Illness, Gastro Intestinal Surgery
Not applicableNot yet recruitingJohn Paul II Catholic University of Lublin802026-02-022026-01-20
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin
FORXIGA - Type 1 Diabetes Mellitus
Phase 2Not yet recruitingSt Vincent's Hospital Melbourne1152026-02-012025-11-06

Showing 20 of 281. Sign in to see all of them.

Narrower conditions

Diabetic Ketoacidosis (73)  ·  Diabetes Mellitus, Type 1 (31)  ·  Diabetes Mellitus (21)  ·  Diabetes Mellitus, Type 2 (19)  ·  Motor Activity (19)  ·  Obesity (13)  ·  Hyperglycemia (12)  ·  Insulin Resistance (12)  ·  Hypoglycemia (9)  ·  Heart Failure (8)  ·  Alzheimer Disease (7)  ·  Epilepsy (7)  ·  Fasting (7)  ·  Hypoxia (6)

Broader conditions

Acid-Base Imbalance (281)  ·  Nutritional and Metabolic Diseases (280)  ·  Acidosis (277)  ·  Metabolic Diseases (275)  ·  Endocrine System Diseases (106)  ·  Diabetes Mellitus (83)  ·  Glucose Metabolism Disorders (76)  ·  Diabetes Complications (72)  ·  Pathological Conditions, Signs and Symptoms (64)  ·  Signs and Symptoms (42)  ·  Behavior (37)  ·  Nervous System Diseases (36)  ·  Immune System Diseases (35)  ·  Autoimmune Diseases (31)

Interventions

formic acid 4-(3-oxobutyl)phenyl ester (16)  ·  Diet, Ketogenic (14)  ·  Ketones (8)  ·  Insulin (7)  ·  Insulin Glargine (7)  ·  dapagliflozin (7)  ·  3-Hydroxybutyric Acid (6)  ·  Blood Specimen Collection (6)  ·  Sodium Chloride (6)  ·  Continuous Glucose Monitoring (5)  ·  Resistance Training (4)  ·  Ringer's Lactate (4)  ·  1,3-butylene glycol (3)  ·  Angptl4 protein, mouse (3)  ·  Diet (3)

Sponsors

Université de Sherbrooke (18)  ·  University of Aarhus (16)  ·  University of British Columbia (12)  ·  Johns Hopkins University (8)  ·  KU Leuven (7)  ·  McGill University (5)  ·  Ohio State University (5)  ·  University of Pennsylvania (5)  ·  Emory University (4)  ·  Western University, Canada (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Assiut University (3)  ·  Boston Children's Hospital (3)  ·  Duke University (3)  ·  Gødstrup Hospital (3)

Countries

United States (94)  ·  Canada (42)  ·  Denmark (27)  ·  Belgium (12)  ·  United Kingdom (11)  ·  Germany (10)  ·  Egypt (5)  ·  France (5)  ·  Italy (5)  ·  Turkey (Türkiye) (5)  ·  Spain (4)  ·  Australia (3)  ·  Czechia (3)  ·  Poland (3)  ·  Argentina (2)

Top investigators

Corinde Wiers, Ph.D. (4)  ·  Eric H Kossoff, MD (4)  ·  Stephen Cunnane, PhD (4)  ·  Jonathan Jun, MD (3)  ·  Antonio Paoli, MD (2)  ·  Christophe De Block, MD, PhD (2)  ·  Guillermo Umpierrez, MD (2)  ·  Jacob T Mey, PhD, RD (2)  ·  Jeff Volek, PhD (2)  ·  Jonathan Little, PhD (2)  ·  Kevin Zemmour, MD (2)  ·  Niels Jessen, Professor (2)

Results publications

PMID 42458538, PMID 33074729, PMID 39804761, PMID 40043832, PMID 41315088, PMID 10064682, PMID 11604980, PMID 15636651, PMID 15840076, PMID 17508198, PMID 19366972, PMID 19664276, PMID 20492042, PMID 20492047, PMID 20621273, PMID 21323778, PMID 21992747, PMID 22685233, PMID 22931483, PMID 23245705, PMID 23689789, PMID 24035670, PMID 24963569, PMID 25275931, PMID 25346490, PMID 25758624, PMID 25905280, PMID 26013711, PMID 26057287, PMID 26064113, PMID 26855664, PMID 27385608, PMID 27912960, PMID 28389705, PMID 28434475, PMID 29716903, PMID 29735284, PMID 29761785, PMID 29897851, PMID 29955713, PMID 30057058, PMID 30506451, PMID 30600227, PMID 31028699, PMID 31067015, PMID 31599919, PMID 31862758, PMID 31918761, PMID 32383792, PMID 32475838

NIH funding

K23HL161348 (2), R21AA031088 (2), 2018 (1), 2023 (1), K01HL169491 (1), P30AG028740 (1), P30AG059297 (1), R01AA031570 (1), R01DK072433 (1), R01DK107680 (1), R01DK112886 (1), R01DK138309 (1), R01NS052592 (1), R01NS052619 (1), R21AA031337 (1)